Table 1.
TuFClot study metastatic breast cancer patient demographics
n (%) | |
---|---|
Receptor status | |
ER+, Her2− | 26 (52) |
ER+, Her2+ | 7 (14) |
ER−, Her2+ | 9 (18) |
Triple negative | 8 (16) |
Metastatic sites | |
Bone only | 6 (12) |
Locally advanced | 3 (6) |
Single visceral site | |
Liver | 12 (24) |
Lung | 12 (24) |
Brain | 2 (4) |
Other | 1 (2) |
Multiple visceral sites (≥ 2) | 14 (28) |
Oestrogen receptor (ER) values were reported as a Modified Quick Score (QS) for all patients. A QS value of 0–2 was considered negative, 3–8 positive